Arrowhead Pharmaceuticals, Inc. (ARWR)

Arrowhead Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cash & Equivalents	127.59	99.19	102.99	100.71	184.43	143.58
Short-Term Investments	770.58	578.28	292.74	268.39	183.36	171.91
Cash & Short-Term Investments	898.17	677.46	395.73	369.1	367.79	315.49
Cash Growth	106.73%	71.19%	7.22%	0.36%	16.58%	21.95%
Receivables	9.7	-	-	1.41	10.26	0.85
Prepaid Expenses	23.69	9.54	8.81	7.29	4.36	4.25
Restricted Cash	2.2	3.5	7.9	7.3	-	-
Other Current Assets	13.16	4.97	4.03	20.2	2.19	1.78
Total Current Assets	946.92	695.47	416.47	405.3	384.6	322.37
Property, Plant & Equipment	425.05	431.29	335.56	168.59	66.02	47.02
Long-Term Investments	-	-	-	105.87	245.6	137.49
Other Intangible Assets	7.29	8.56	10.26	11.96	13.66	15.36
Other Long-Term Assets	1.35	4.48	3.26	0.22	0.27	0.26
Total Assets	1,381	1,140	765.55	691.94	710.15	522.5
Accounts Payable	33.05	11.39	35.87	2.87	9.46	6.83
Accrued Expenses	83.77	80.8	43.68	59.11	23.77	13.45
Current Portion of Long-Term Debt	40	-	-	-	-	-
Current Portion of Leases	7.01	6.34	10.56	2.78	2.25	1.1
Current Unearned Revenue	22.98	-	0.87	74.1	111.06	19.29
Other Current Liabilities	7.72	4.64	14.48	-	-	0.02
Total Current Liabilities	194.53	103.17	105.46	138.85	146.54	40.68
Long-Term Debt	560.59	734.54	268.33	-	-	-
Long-Term Leases	105.69	111.03	104.61	78.8	23.3	20.04
Long-Term Unearned Revenue	-	-	-	55.95	131.5	-
Total Liabilities	860.81	948.74	478.39	273.6	301.33	60.73
Common Stock	0.23	0.22	0.2	0.2	0.2	0.2
Additional Paid-In Capital	2,120	1,806	1,300	1,219	1,053	965.41
Retained Earnings	-1,603	-1,626	-1,026	-820.76	-644.69	-503.84
Comprehensive Income & Other	5.36	4.75	-3.22	-0.14	-0.07	0.02
Total Common Equity	522.31	185.44	271.34	398.52	408.82	461.78
Minority Interest	-2.51	5.62	15.82	19.82	-	-
Shareholders' Equity	519.81	191.06	287.16	418.34	408.82	461.78
Total Liabilities & Equity	1,381	1,140	765.55	691.94	710.15	522.5
Total Debt	713.29	851.91	383.5	81.58	25.55	21.14
Net Cash (Debt)	184.89	-174.45	12.23	287.52	342.24	294.36
Net Cash Growth	-	-	-95.75%	-15.99%	16.27%	13.78%
Net Cash Per Share	1.42	-1.46	0.11	2.73	3.30	2.92
Filing Date Shares Outstanding	138.26	124.43	107.43	106.01	104.53	102.76
Total Common Shares Outstanding	138.14	124.38	107.31	105.96	104.33	102.38
Working Capital	752.39	592.3	311.02	266.45	238.06	281.69
Book Value Per Share	3.78	1.49	2.53	3.76	3.92	4.51
Tangible Book Value	515.03	176.88	261.08	386.56	395.16	446.42
Tangible Book Value Per Share	3.73	1.42	2.43	3.65	3.79	4.36
Land	3	3	3	3	-	-
Buildings	249.25	75.99	-	-	-	-
Machinery	82.76	71.93	58.75	40.47	29.67	21.32
Construction In Progress	15.87	188.73	166.66	56.37	0.35	-
Leasehold Improvements	104.4	104.41	103.81	42.02	41.52	25.24

Updated Aug 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q